Open access · CC-BY
via OpenAlex
A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer’s disease
Courtney L. Millar, Ike Iloputaife, Kathryn Baldyga, Amani M. Norling, Afroditi Boulougoura, Theodoros Vichos, Tamar Tchkonia, Aaron M Deisinger, Tamar Pirtskhalava, James L. Kirkland, Thomas G. Travison, Lewis Arnold Lipsitz
EBioMedicine · 2025 · ▲ 87 citations
Abstract
BACKGROUND: This single-arm study evaluates the feasibility, safety, and preliminary effects of two senolytic agents, Dasatinib and Quercetin (DQ), in older adults at risk of Alzheimer's disease. METHODS: Participants took 100 mg of Dasatinib and 1250 mg of Quercetin for two days every two weeks over 12 weeks. Recruitment rate, adverse events, absolute changes in functional outcomes, and percent changes in biomarkers were calculated. Spearman correlations between functional and biomarker outcomes were performed. FINDINGS: Approximately 10% of telephone-screened individuals completed the intervention (n = 12). There were no serious adverse events related to the intervention. Mean Montreal Cognitive Assessment (MoCA) scores non-significantly increased following DQ by 1.0 point (95% CI: -0.7, 2.7), but increased significantly by 2.0 points (95% CI: 0.1, 4.0) in those with lowest baseline MoCA scores. Mean percent change in tumour necrosis factor-alpha (TNF-α), a key product of the senescence(definition)-associated secretory phenotype (SASP), non-significantly decreased following DQ by -3.0% (95% CI: -13.0, 7.1). Changes in TNF-α were significantly and inversely correlated with changes in MoCA scores (r = -0.65, p = 0.02), such that reductions in TNF- α were correlated with increases in MoCA scores. INTERPRETATION: This study suggests that intermittent DQ treatment is feasible and safe; data hint at potential functional benefits in older adults at risk of Alzheimer's disease. The observed reduction in TNF-α and its correlation with increases in MoCA scores suggests that DQ may improve cognition by modulating the SASP. However, there was not an appropriate control group. Data are preliminary and must be interpreted cautiously. FUNDING: National Institute on Ageing grants R21AG073886 and R33AG061456 funded this research.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.ebiom.2025.105612
- Canonical
- link ↗
- Fetched
- 2026-10-30 MST
Cite this
APA
Millar, C.L., Iloputaife, I., Baldyga, K., Norling, A.M., Boulougoura, A., Vichos, T., Tchkonia, T., Deisinger, A.M., Pirtskhalava, T., Kirkland, J.L., Travison, T.G., & Lipsitz, L.A. (2025). A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer’s disease. <em>EBioMedicine</em>. https://doi.org/10.1016/j.ebiom.2025.105612
Vancouver
Millar CL, Iloputaife I, Baldyga K, Norling AM, Boulougoura A, Vichos T, et al. A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer’s disease. EBioMedicine. 2025. doi:10.1016/j.ebiom.2025.105612.
BibTeX
@article{courtney2025Apilot,
title = {A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer’s disease},
author = {Courtney L. Millar and Ike Iloputaife and Kathryn Baldyga and Amani M. Norling and Afroditi Boulougoura and Theodoros Vichos and Tamar Tchkonia and Aaron M Deisinger and Tamar Pirtskhalava and James L. Kirkland and Thomas G. Travison and Lewis Arnold Lipsitz},
journal = {EBioMedicine},
year = {2025},
doi = {10.1016/j.ebiom.2025.105612},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of the Endocrine Society 2024
Open access · CC-BY
6711 Single Nuclei RNA-seq To Map Adipose Cellular Populations And Senescent Cells In Response To A Lifestyle Or Senolytic Intervention In Older Adults With Obesity: A Double-Blind, Placebo-Controlled, Randomized Trial
Lewis Lipsitz 2022
Open access · US-GOV
Senolytics To Alleviate Mobility Issues and Neurological Impairment in Aging
Diabetes 2024
Citation only
10-PUB: Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Response to a Lifestyle or Senolytic Intervention in Older Adults with Obesity—A Double-Blind, Placebo-Controlled, Randomized Trial
medtigo Journal of Medicine 2025
Open access · CC-BY
Senescence and Beyond: Exploring Senolytic Strategies for Chronic Disease
Nature Medicine 2023
Preprint · CC-BY
Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial
JAMA 2019
Open access · OA